Reference	Country	Type of DM	Population (Age)	Intervention Evaluated	Comparators	Time Horizon	CHEERS 2022[@404703] ^a	Outcomes Measure
Javitt (1990)[@404704]	US	T1D	Debutant patients (mean, 12.5 y)	Screening and treatment of ophthalmic diabetes complications	No screening strategy	Lifetime	24/26 items	Sight years saved/reading sight years saved/cost savings
Palmer (2000)[@404705]	Switzerland	T1D	19 y/o patients	Conventional treatment with insulin (Conv)	Conv + Retinopathy Screening (RS) /Conv + Microalbuminuria and iACE treatment (MS-iACE) /Conv + RS + MS-iACE/Intensive insulin treatment (Int) /Int + RS/Int + MS-iACE /Int + RS + MS-iACE	Lifetime	24/25 items	LYG
Roze (2005)[@404706]	UK	T1D	Adults^b (mean, 26 y/o; mean duration of DM: 12 y)	CSII	Insulin MDI	Lifetime	24/25 items	LYG and QALY
Cohen (2007)[@404707]	Australia	T1D	Adults^b and adolescents (mean, 17 y/o; mean duration of DM: 6 y)	CSII	Insulin MDI	60 y	24/25 items	LYG and QALY
Dall (2009)[@404708]	US	T1D, T2D	Patients of all ages	Not specified	^c	Not specified	17/22 items	^c
Gschwend (2009)[@404709]	Belgium, France, Germany, Italy and Spain	T1D	Patients 18-75 y/o	Detemir insulin	NPH + pre-prandial aspart insulin	50 y	19/25 items	QALY
Beckwith (2011)[@404710]	US	T1D	20 y/o patients with an acute hypoglycemic episode	Islet transplantation	Insulin therapy	20 y	23/25 items	QALY
Pfhol (2012)[@404711]	Germany	T1D	Adults^b (mean, 34.8 y/o; SD, 10 y)	Glargine insulin	Intensive NPH therapy	40 y	24/25 items	LYG and QALY
Gómez (2016)[@404712]	Colombia	T1D	Adults^b (mean, 34.19 y/o; SD, 17.14 y)	Insulin pump with a CGM device	Insulin MDI	55 y	24/25 items	LYG and QALY
Sussman (2016)[@404713]	US	T1D, T2D	Pediatric and adult patients in T1D/Adult patients in T2D	Insulin therapy with a technology that reduces risk of hypoglycemia	Insulin therapy without a technology that reduces the risk of hypoglycemia	1 y	22/25 items	Hypoglycemic episodes avoided
Dawoud (2017)[@404714]	UK	T1D	Adults^b (mean, 42.98 y/o; SD, 19.14 y)	Daily NPH	Daily detemir insulin /twice a day detemir insulin /Glargine insulin 100 IU /Degludec insulin /Twice a day NPH /4 times a day NPH	Lifetime	24/25 items	QALY
Roze (2017)[@404715]	Denmark	T1D	Adults with hyperglycemia at baseline^b (mean, 27.0 y/o; SD, 15.6 y) Adults with hypoglycemic risk at baseline^b (mean, 18.6 y/o; SD, 11.8 y)	Insulin SAP	CSII	Not specified	24/25 items	QALY
Thomas (2017)[@404716]	UK	T2D	Patients >16 y/o	Diabetes prevention program	No prevention program	20 y	24/25 items	LYG, QALY and social return of the investment of £1
GoodSmith (2019)[@404717]	US	T1D, T2D	Patients 10-20 y/o	MODY genes screening	No genetic screening	10 and 30 y	24/25 items	LYG and QALY
Roze (2019)[@404718]	Turkey	T1D	Adults with hyperglycemia at baseline^b (mean, 27.0 y/o; SD, 15.6 y) Adults with hypoglycemic risk at baseline^b (mean, 18.6 y/o; SD, 11.8 y)	Insulin SAP	CSII	Lifetime	24/25 items	QALY
McQueen (2020)[@404719]	US	T1D	Patients 2-17 y/o (mean: 9.3 y)	Autoimmune screening for kids and routine screening for diabetes	Habitual care in diabetes	Lifetime	23/25 items	QALY
Roze (2021)[@404720]	UK	T1D	Adult and adolescent patients (mean, 37.8 y/o; SD, 16.5 y)	Insulin pump	CSII	Lifetime	24/25 items	QALY
Pease (2022)[@404721]	Australia	T1D	12 y/o patients	CGM funded by the National Health System	CGM funded by the patient	9 y	24/25 items	QALY
Zhang (2022)[@404722]	China	T1D	Patients <18 y/o	CSII	MDI	70 y	23/25 items	LYG and QALY